Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

IBIO

iBio Inc

Mar 12 • 04:00PM ET

5.55

Dollar change -0.17
Percentage change -2.97	%

Healthcare • Biotechnology • USA • NASD

Peers: NVAX ARCT INO CODX OCGN VXRT ADMA IBRX ALT APRE

| Held by: VXF DFAT

Index	-	P/E	-	EPS (ttm)	-2.70	Insider Own	6.12%	Shs Outstand	9.87M	Perf Week	-12.32%
Market Cap	54.80M	Forward P/E	-	EPS next Y	-1.38	Insider Trans	66.25%	Shs Float	9.27M	Perf Month	62.28%
Income	-19.30M	PEG	-	EPS next Q	-0.32	Inst Own	26.65%	Short Float	9.74%	Perf Quarter	100.36%
Sales	0.38M	P/S	144.21	EPS this Y	60.55%	Inst Trans	2.89%	Short Ratio	2.09	Perf Half Y	195.21%
Book/sh	1.52	P/B	3.66	EPS next Y	13.52%	ROA	-51.09%	Short Interest	0.90M	Perf Year	370.34%
Cash/sh	0.71	P/C	7.82	EPS next 5Y	45.01%	ROE	-123.28%	52W Range	1.05 - 6.89	Perf YTD	126.53%
Dividend Est.	-	P/FCF	-	EPS past 5Y	57.55%	ROI	-113.63%	52W High	-19.46%	Beta	0.87
Dividend TTM	-	Quick Ratio	1.76	Sales past 5Y	-18.92%	Gross Margin	-212.53%	52W Low	428.57%	ATR (14)	0.61
Dividend Ex-Date	-	Current Ratio	1.76	EPS Y/Y TTM	89.72%	Oper. Margin	-4149.33%	RSI (14)	62.10	Volatility	11.02% 15.26%
Employees	19	Debt/Eq	0.30	Sales Y/Y TTM	650.00%	Profit Margin	-5147.47%	Recom	1.00	Target Price	4.80
Option/Short	No / Yes	LT Debt/Eq	0.22	EPS Q/Q	89.20%	Payout	-	Rel Volume	0.48	Prev Close	5.72
Sales Surprise	-	EPS Surprise	-4.35%	Sales Q/Q	-	Earnings	Feb 10 BMO	Avg Volume	431.74K	Price	5.55
SMA20	17.37%	SMA50	52.95%	SMA200	112.27%	Trades		Volume	208,793	Change	-2.97%

Date	Action	Analyst	Rating Change	Price Target Change
May-28-24	Initiated	Chardan Capital Markets	Buy	$5
Nov-29-21	Initiated	JMP Securities	Mkt Outperform	$1.50
Jan-22-21	Initiated	Cantor Fitzgerald	Overweight	$3
Jun-26-20	Initiated	Alliance Global Partners	Buy	$2.55

Feb-19-25 04:05PM	iBio to Begin Trading on the Nasdaq Stock Exchange (GlobeNewswire) -5.71%
Feb-17-25 04:38PM	Is Ibio, Inc. (IBIO) Among Stocks Insiders Are Buying This Year? (Insider Monkey)
Feb-10-25 04:05PM	iBio Reports Fiscal Second Quarter 2025 Financial Results (GlobeNewswire) -8.06% -7.31%
Jan-13-25 07:00AM	iBio Announces New Investments from Board Members and Officers (GlobeNewswire)
Jan-07-25 07:00AM	iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio (GlobeNewswire) +10.16%
07:58AM	Loading…
Jan-03-25 07:58AM	iBio Expands Pipeline with New Antibody Agreement (TipRanks)
Jan-02-25 09:24AM	Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed Platform (Benzinga)
07:00AM	iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio (GlobeNewswire)
Nov-25-24 08:00AM	iBio Strengthens Board with Appointment of Two New Independent Directors (GlobeNewswire)
Nov-12-24 04:05PM	iBio Reports Fiscal First Quarter 2025 Financial Results (GlobeNewswire) -9.02%
Oct-10-24 08:00AM	iBio and AstralBio Provide Update on Myostatin Program for Obesity (GlobeNewswire) -7.75%
Sep-20-24 04:05PM	iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -6.09%
Sep-03-24 07:00AM	iBio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-12-24 04:30PM	iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development (GlobeNewswire) +23.42%
Jun-03-24 07:00AM	iBio Closes Sale of Manufacturing Facility in Texas (GlobeNewswire)
04:05PM	Loading…
May-13-24 04:05PM	iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-05-24 02:35PM	3 Healthcare Stocks Short Sellers Are Prescribing for Trouble (InvestorPlace) -15.26%
Mar-27-24 07:00AM	iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases (GlobeNewswire) +192.17%
Mar-26-24 07:35PM	iBio Announces $15.0 Million Private Placement (GlobeNewswire) +5.02%
Mar-24-24 03:54PM	12 Best Biotech Penny Stocks to Invest In (Insider Monkey)
Feb-26-24 07:45AM	iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka (GlobeNewswire)
Jan-16-24 08:15AM	iBio Announces Participation in 23rd Annual PepTalk Conference (GlobeNewswire)
Dec-26-23 07:15AM	iBio Amends and Extends Maturity of Credit Agreement (GlobeNewswire)
Dec-05-23 08:00AM	iBio, Inc. Announces Pricing of $4.5 Million Public Offering (GlobeNewswire) -50.00%
Nov-27-23 05:20PM	iBio Announces Reverse Stock Split (GlobeNewswire) -31.03%
Nov-01-23 08:24AM	iBio Further Expands Tech Stack with ShieldTx; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific (GlobeNewswire)
Oct-10-23 08:00AM	iBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics (GlobeNewswire) +7.14%
Oct-02-23 06:45AM	iBio Explains Recent Filing of Registration Statement (GlobeNewswire)
Sep-27-23 04:19PM	iBio Announces Filing of 2023 Annual Report on SEC Form 10-K (GlobeNewswire)
Sep-21-23 04:05PM	iBio Announces Amendment to Credit Agreement with Woodforest (GlobeNewswire)
04:15PM	Loading…
Aug-14-23 04:15PM	iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development (GlobeNewswire) -6.53%
Jun-27-23 08:00AM	iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Companys Next Stage of Growth (GlobeNewswire) -7.38%
Jun-20-23 08:25AM	3 Millionaire-Maker Biotech Stocks to Buy and Hold Forever (InvestorPlace)
Jun-12-23 04:15PM	iBio Forges Research Collaboration with the National Institutes of Health (GlobeNewswire)
Jun-06-23 08:00AM	iBio Expands Tech Stack with EngageTx; Adds TROP-2 Bispecific to Development Pipeline (GlobeNewswire) +9.25%
May-09-23 04:30PM	iBio to Participate in the JMP Securities Life Sciences Conference (GlobeNewswire)
Apr-04-23 04:05PM	iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform (GlobeNewswire) -12.35% -18.12%
Mar-31-23 08:10AM	iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing (GlobeNewswire)
Feb-16-23 04:48PM	iBio Announces MUC16 as its Latest Immune-Oncology Target Program (GlobeNewswire) -11.86% +97.28%
Jan-05-23 08:00AM	iBio Announces Issuance of U.S. Patent Covering AI-Engineered Epitope Discovery Engine (GlobeNewswire) -5.23%
Dec-09-22 04:05PM	iBio Announces Closing of $3.5 Million Underwritten Public Offering (GlobeNewswire) -7.16%
Dec-06-22 11:27PM	iBio Announces Pricing of $3.5 Million Underwritten Public Offering (GlobeNewswire) -57.88%
04:01PM	iBio Announces Proposed Underwritten Public Offering (GlobeNewswire)
08:00AM	iBio to Participate in the JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Dec-05-22 08:00AM	iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022 (GlobeNewswire)
Dec-02-22 04:30PM	iBio Announces CEO Departure (GlobeNewswire) +6.25%
Nov-03-22 08:00AM	iBio Accelerates Transformation to AI-Powered Biotech (GlobeNewswire) -9.71%
Oct-27-22 06:40PM	7 Penny Stocks to Sell Pronto Before a Painful Downturn (InvestorPlace) -5.14%
Sep-30-22 11:48AM	3 Healthcare Stocks to Sell Before They Die (InvestorPlace) -6.53%
Sep-27-22 04:30PM	Edited Transcript of IBIO.A earnings conference call or presentation 27-Sep-22 8:30pm GMT (Thomson Reuters StreetEvents) -32.28%
04:10PM	iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Sep-21-22 08:30AM	iBio Acquires RubrYc Therapeutics AI Drug Discovery Platform and Pipeline (GlobeNewswire) +12.18%
Aug-16-22 09:00AM	iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate (GlobeNewswire)
May-18-22 08:00AM	iBio to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire) -7.55%
May-16-22 10:25AM	iBio (IBIO) Q3 2022 Earnings Call Transcript (Motley Fool)
May-12-22 04:05PM	iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +10.12% -7.00%
May-09-22 08:00AM	iBio Demonstrates Efficacy of an IL-2 Sparing Anti-CD25 Antibody Produced Using its FastPharming System for Treg Depletion in Cancer (GlobeNewswire)
May-05-22 04:30PM	iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022 (GlobeNewswire) -8.38%
May-02-22 08:00AM	iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants (GlobeNewswire)
Mar-11-22 08:00AM	iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire)
Feb-14-22 04:05PM	iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-07-22 04:30PM	iBio to Report Fiscal 2022 Second Quarter Financial Results and Provide Corporate Update on Monday, February 14, 2022 (GlobeNewswire)
Jan-26-22 11:21AM	iBio Advances Its Vaccine Program for Multi-Variant COVID-19 Disease (Benzinga)
09:00AM	iBio Announces Progression of Vaccine Program for Multi-Variant COVID-19 Disease (GlobeNewswire)
Jan-04-22 04:30PM	iBio Announces Participation in the H.C. Wainwright BioConnect Conference (GlobeNewswire) -6.78%
Dec-22-21 09:25AM	iBio Announces Partial Adjournment of Annual Meeting of Shareholders to January 31, 2022 (GlobeNewswire)
Dec-21-21 09:20AM	iBio Provides Information for Listening to the Virtual Annual Stockholder Meeting (GlobeNewswire)
Dec-10-21 08:30AM	iBio Announces Partial Adjournment of Annual Meeting to December 22 (GlobeNewswire)
Nov-30-21 11:57AM	10 Biotech Penny Stocks to Buy Now (Insider Monkey) -12.73%
08:00AM	ISS Joins Glass Lewis in Recommending Shareholders Vote FOR All Proposals Ahead of iBios Upcoming Annual Meeting (GlobeNewswire)
Nov-29-21 08:45AM	Omicron Variant Underscores Need for New COVID Vaccine Candidates Like IBIO-202 (GlobeNewswire) +29.15%
Nov-17-21 04:30PM	Leading Independent Proxy Advisory Firm, Glass Lewis, Recommends iBio Shareholders Vote FOR All Proposals Ahead of Annual Meeting (GlobeNewswire) -6.08%
Nov-15-21 04:05PM	iBio Reports Fiscal First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -7.97%
01:00PM	iBio Announces Collaboration with UT Southwestern to Investigate IBIO-100 in Solid Tumors (GlobeNewswire)
Nov-08-21 04:30PM	iBio to Report Fiscal 2022 First Quarter Financial Results and Provide Corporate Update on Monday, November 15, 2021 (GlobeNewswire)
Nov-03-21 04:47PM	iBio Acquires FastPharming Manufacturing Facility® (GlobeNewswire) +9.08%
Oct-26-21 08:35AM	iBio Urges Shareholders to Vote FOR All Proposals Ahead of its Upcoming Annual Meeting to be Held on December 9 (GlobeNewswire)
Oct-02-21 07:31AM	This Under-the-Radar Pharma Company Could Be a Bargain Hunter's Dream (Motley Fool)
Sep-27-21 07:30AM	iBio Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Sep-20-21 04:30PM	iBio to Participate in the Cantor 2021 Virtual Global Healthcare Conference (GlobeNewswire) -7.32%
07:30AM	iBio to Report Fiscal Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Monday, September 27, 2021 (GlobeNewswire)
Sep-07-21 04:30PM	iBio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-26-21 07:00AM	iBio Appoints William D. Clark to its Board of Directors (GlobeNewswire)
Aug-25-21 11:16AM	iBio Expands Immuno-Oncology Pipeline With RubrYc Deal (Benzinga)
07:30AM	iBio Expands Immuno-Oncology Pipeline in AI Partnership with RubrYc Therapeutics (GlobeNewswire)
Jul-15-21 05:10PM	iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate (GlobeNewswire)
Jul-09-21 06:10AM	IBio Stock Ticks Higher After Adding Three Cancer Antibody Programs (Benzinga)
Jul-08-21 04:15PM	iBio Establishes Oncology Drug Discovery Pipeline with Three New Antibody Programs (GlobeNewswire)
Jun-18-21 09:13PM	Is IBIO Stock A Buy Here? (Insider Monkey)
Jun-09-21 04:30PM	iBio Further Strengthens Board with Appointment of Veteran Biopharmaceutical Executive, Eef Schimmelpennink (GlobeNewswire) +6.04%
May-19-21 04:30PM	iBio to Present at the UBS Global Healthcare Virtual Conference (GlobeNewswire)
May-17-21 07:00AM	iBio Reports Fiscal Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) -7.48%
06:15AM	iBio, Inc. to Host Earnings Call (ACCESSWIRE)
May-10-21 08:15AM	iBio to Report Fiscal 2021 Third Quarter Financial Results and Provide Corporate Update on Monday, May 17, 2021 (GlobeNewswire)
May-08-21 10:15AM	Here's Why iBio Stock Surged Friday (Motley Fool)
May-07-21 11:52AM	IBIO Stock: The Covid-19 Vaccine News Sending iBio Soaring Today (InvestorPlace) +16.67%
07:01AM	iBio Stock Is Trading Higher After Announcing Next-Gen COVID-19 Vaccine Candidate (Benzinga)
May-05-21 08:42PM	Why iBio Stock Soared Today (Motley Fool) +14.73% -6.76%
May-04-21 05:00PM	iBio and Fraunhofer USA Conclude Litigation and Enter License Agreement (GlobeNewswire)
Mar-12-21 05:13PM	iBio Stock Is Not Likely To Move Higher Given Its Huge Dilution (InvestorPlace)

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Duran Felipe	Chief Financial Officer	Jan 10 '25	Buy	2.72	9,191	25,000	11,139	Jan 13 04:34 PM
Brenner Martin	See Remarks	Jan 10 '25	Buy	2.72	9,191	25,000	18,316	Jan 13 04:34 PM
Banjak Marc	Chief Legal Officer	Jan 10 '25	Buy	2.72	9,191	25,000	11,066	Jan 13 04:33 PM
Arkowitz David	Director	Jan 10 '25	Buy	2.72	18,382	49,999	18,382	Jan 13 04:32 PM
Clark William D	Director	Jan 10 '25	Buy	2.72	1,838	4,999	1,838	Jan 13 04:31 PM
Parada Antonio Bernardino Guim	Director	Jan 10 '25	Buy	2.72	183,823	499,999	183,823	Jan 13 04:30 PM
Sender Gary	Director	Jan 10 '25	Buy	2.72	9,191	25,000	9,191	Jan 13 04:30 PM

Open in Screener

MCRB

Seres Therapeutics Inc

Mar 12 • 04:00PM ET

0.6932

Dollar change -0.0252
Percentage change -3.51	%

Healthcare • Biotechnology • USA • NASD

MCRB Seres Therapeutics Inc daily Stock Chart

Peers: CRSP FATE NTLA BPMC SANA EDIT BLUE ADPT XBIO CLRB

| Held by: VTI VXF SCHA VHT SCHB QQQS BTEC

Index	-	P/E	-	EPS (ttm)	-1.19	Insider Own	26.90%	Shs Outstand	170.20M	Perf Week	-9.37%
Market Cap	120.69M	Forward P/E	-	EPS next Y	-0.33	Insider Trans	-0.13%	Shs Float	127.27M	Perf Month	-11.75%
Income	-172.18M	PEG	-	EPS next Q	-0.20	Inst Own	22.97%	Short Float	13.54%	Perf Quarter	-15.80%
Sales	0.06M	P/S	2011.54	EPS this Y	86.52%	Inst Trans	-0.79%	Short Ratio	11.41	Perf Half Y	-32.70%
Book/sh	0.14	P/B	4.93	EPS next Y	-175.37%	ROA	-60.50%	Short Interest	17.23M	Perf Year	-28.57%
Cash/sh	0.38	P/C	1.81	EPS next 5Y	25.41%	ROE	-3758.21%	52W Range	0.54 - 1.53	Perf YTD	-16.58%
Dividend Est.	-	P/FCF	-	EPS past 5Y	18.22%	ROI	-157.70%	52W High	-54.69%	Beta	2.51
Dividend TTM	-	Quick Ratio	1.12	Sales past 5Y	477.44%	Gross Margin	-13081.25%	52W Low	28.37%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	1.12	EPS Y/Y TTM	-5.95%	Oper. Margin	-225450.00%	RSI (14)	39.74	Volatility	7.86% 7.32%
Employees	233	Debt/Eq	3.91	Sales Y/Y TTM	-99.95%	Profit Margin	-269034.37%	Recom	2.43	Target Price	3.31
Option/Short	Yes / Yes	LT Debt/Eq	3.56	EPS Q/Q	-1.74%	Payout	-	Rel Volume	0.58	Prev Close	0.72
Sales Surprise	-100.00%	EPS Surprise	848.39%	Sales Q/Q	-100.00%	Earnings	Mar 13 BMO	Avg Volume	1.51M	Price	0.69
SMA20	-9.91%	SMA50	-13.69%	SMA200	-20.92%	Trades		Volume	879,114	Change	-3.51%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-24-24	Downgrade	JP Morgan	Neutral → Underweight
Jun-26-23	Resumed	Oppenheimer	Outperform	$12
Apr-21-23	Initiated	JP Morgan	Neutral	$7
Jul-23-21	Downgrade	Goldman	Neutral → Sell	$24 → $7
May-18-21	Resumed	Goldman	Neutral	$24
Mar-05-21	Upgrade	Chardan Capital Markets	Neutral → Buy	$30
Sep-18-20	Downgrade	Chardan Capital Markets	Buy → Neutral	$32.50 → $27.50
Aug-18-20	Initiated	Piper Sandler	Overweight	$40
Aug-11-20	Upgrade	Jefferies	Hold → Buy	$4 → $29
Aug-11-20	Reiterated	H.C. Wainwright	Buy	$8 → $41
Apr-30-19	Initiated	Jefferies	Hold	$7
Oct-22-18	Initiated	Chardan Capital Markets	Buy	$15
Oct-13-17	Initiated	Oppenheimer	Outperform	$19
Aug-04-17	Reiterated	H.C. Wainwright	Buy	$15 → $19
Feb-01-17	Reiterated	FBR & Co.	Outperform	$23 → $18
Aug-12-16	Reiterated	FBR Capital	Outperform	$43 → $23
Aug-01-16	Reiterated	H.C. Wainwright	Buy	$50 → $15
Aug-01-16	Downgrade	BofA/Merrill	Buy → Neutral
Jul-29-16	Resumed	H.C. Wainwright	Buy	$50
Mar-30-16	Initiated	FBR Capital	Outperform	$40

Show Previous Ratings

Mar-04-25 07:00AM	Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025 (GlobeNewswire) -10.50%
Mar-03-25 07:00AM	Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach (GlobeNewswire)
Jan-16-25 07:00AM	Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale (GlobeNewswire) -5.77%
Jan-10-25 07:15AM	Seres announces new translational biomarker results from SER-155 Phase 1b study (TipRanks)
Jan-09-25 07:00AM	Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates (GlobeNewswire)
07:30AM	Loading…
Dec-17-24 07:30AM	Seres Therapeutics to highlight plans for SER-155 at JPMorgan conference (TipRanks)
Dec-16-24 07:00AM	Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-24 05:43AM	Seres SER-155 gains breakthrough status for BSIs reduction (Pharmaceutical Technology) +9.20%
Dec-09-24 07:00AM	FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) (GlobeNewswire)
Nov-22-24 07:00AM	Seres Therapeutics to Participate in Piper Sandler Healthcare Conference (GlobeNewswire) +5.03%
Nov-14-24 02:08AM	Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ... (GuruFocus.com)
Nov-13-24 07:23AM	Seres Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) -11.10%
07:00AM	Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-06-24 07:00AM	Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024 (GlobeNewswire) -6.98%
Sep-30-24 05:15PM	Seres Therapeutics Announces Completion of VOWST Asset Sale to Societe des Produits Nestle S.A (GlobeNewswire)
05:15PM	Loading…
05:15PM	Seres Therapeutics Announces Completion of VOWST Asset Sale to Soci t des Produits Nestl S.A (GlobeNewswire)
Sep-27-24 03:26PM	Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestle (Business Wire) +10.44%
Sep-26-24 04:01PM	Seres Therapeutics Stockholders Approve Sale of VOWST to Nestle Health Science; Sale Expected to Close on September 30 (GlobeNewswire) -9.10%
04:01PM	Seres Therapeutics Stockholders Approve Sale of VOWST to Nestl Health Science; Sale Expected to Close on September 30 (GlobeNewswire)
Sep-13-24 07:00AM	Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference (GlobeNewswire)
Sep-12-24 07:00AM	Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) (GlobeNewswire) -8.57%
Sep-04-24 09:35AM	After Plunging -22.45% in 4 Weeks, Here's Why the Trend Might Reverse for Seres Therapeutics (MCRB) (Zacks)
Aug-15-24 09:55AM	Bears are Losing Control Over Seres Therapeutics (MCRB), Here's Why It's a 'Buy' Now (Zacks)
Aug-14-24 03:09AM	Q2 2024 Seres Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +9.07%
Aug-13-24 07:15AM	Seres Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) -6.97%
07:00AM	Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-06-24 07:00AM	Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024 (GlobeNewswire) -21.09%
07:00AM	Seres Therapeutics Announces Signing of VOWST Asset Purchase Agreement with Nestle Health Science (GlobeNewswire)
07:00AM	Seres Therapeutics Announces Signing of VOWST Asset Purchase Agreement with Nestl Health Science (GlobeNewswire)
Jun-12-24 07:00AM	Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer (PR Newswire) -6.18%
04:00PM	Loading…
Jun-07-24 04:00PM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -28.03% +20.54%
Jun-06-24 07:05AM	Seres, indebted and in need of cash, agrees to sell microbiome pill to Nestle (BioPharma Dive) -25.17%
07:00AM	Nestl Health Science agrees to acquire global rights to VOWST, product it launched in June 2023 (PR Newswire)
06:30AM	Seres Therapeutics Enters Into Memorandum of Understanding For Vowst Asset Sale to Nestle Health Science (GlobeNewswire)
06:30AM	Seres Therapeutics Enters Into Memorandum of Understanding For Vowst Asset Sale to Nestl Health Science (GlobeNewswire)
May-13-24 12:18PM	Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2024 Earnings Call Transcript (Insider Monkey) -5.38%
May-09-24 11:06AM	Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating (MT Newswires) +37.44%
07:00AM	Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management (PR Newswire)
06:30AM	Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating (MT Newswires)
03:11AM	Seres Therapeutics Inc (MCRB) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ... (GuruFocus.com)
May-08-24 11:54AM	MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -32.49%
08:42AM	Seres Therapeutics Reports Q1 2024 Earnings: Surpasses Revenue Estimates (GuruFocus.com)
07:25AM	Seres Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
May-06-24 04:01PM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.72%
09:30AM	Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024 (Business Wire)
Apr-09-24 07:00AM	Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT (Business Wire)
Apr-08-24 08:00AM	Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences (PR Newswire)
Mar-28-24 07:00AM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-19-24 08:30AM	Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024 (PR Newswire) +6.34%
07:00AM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-13-24 03:32PM	11 Oversold NASDAQ Stocks To Buy Right Now (Insider Monkey)
08:17AM	11 Oversold Healthcare Stocks To Buy Right Now (Insider Monkey)
Mar-07-24 11:48AM	Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 02:17AM	Q4 2023 Seres Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-05-24 09:51AM	MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -7.02%
07:32AM	Seres Therapeutics Inc (MCRB) Reports Encouraging Sales Growth and Strategic Cost Savings in 2023 (GuruFocus.com)
07:00AM	Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates (Business Wire)
Feb-28-24 07:00AM	Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024 (Business Wire)
Feb-27-24 07:00AM	Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference (Business Wire) +6.54%
Feb-26-24 07:00AM	Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz (Business Wire)
Jan-17-24 07:00AM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-09-24 08:44AM	DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING (PR Newswire) -8.33%
07:00AM	Seres Therapeutics Announces VOWST Commercial Launch Update and US FDA Fast Track Designation for SER-155 (Business Wire)
Jan-08-24 06:30AM	Flagship Pioneering Debuts Enabling Technologies Initiative (PR Newswire) +11.43%
06:30AM	Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine (PR Newswire)
Jan-04-24 04:00PM	Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +5.26%
Dec-07-23 07:46PM	Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023 (Business Wire)
Nov-28-23 09:18AM	Seres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ET (Business Wire)
Nov-27-23 07:01PM	Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders (PR Newswire)
Nov-21-23 06:00AM	Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics (PR Newswire) +7.72%
Nov-05-23 02:22PM	Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 08:47AM	Seres Therapeutics Inc (MCRB) Announces Q3 2023 Financial Results and Strategic Restructuring (GuruFocus.com) -35.25%
07:32AM	Seres Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST Net Sales of $7.6 Million (Business Wire)
Nov-01-23 10:30AM	Flagship Pioneering Launches Pioneering Intelligence (PR Newswire) -5.88%
Oct-30-23 05:30PM	Seres Therapeutics to Announce Third Quarter 2023 Results on Thursday, November 2, 2023; Host Conference Call and Webcast at 8:00 a.m. EST (Business Wire) +5.07% +5.52%
Oct-19-23 10:30AM	Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines (PR Newswire)
Oct-12-23 07:00AM	Seres Therapeutics to Highlight VOWST Data at IDWeek (Business Wire) -12.72%
Oct-06-23 07:00AM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.68%
Oct-02-23 07:00AM	Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics (PR Newswire) -9.66%
Sep-27-23 08:31AM	Flagship Pioneering Named to Fortune's 2023 'Change the World' List (PR Newswire)
Sep-11-23 06:30AM	Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer (PR Newswire)
Sep-08-23 07:00AM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-07-23 10:00AM	Seres Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (Business Wire)
Aug-29-23 09:00AM	Invaio achieves first registration for citrus greening solution featuring Trecise technology (PR Newswire)
Aug-09-23 06:27AM	Investors Don't See Light At End Of Seres Therapeutics, Inc.'s (NASDAQ:MCRB) Tunnel (Simply Wall St.) -6.06%
Aug-08-23 08:25AM	Seres Therapeutics (MCRB) Misses Q2 Earnings Estimates (Zacks) -6.94%
07:19AM	Seres Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates (Business Wire)
Aug-04-23 07:00AM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-01-23 07:00AM	Seres Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference (Business Wire)
07:00AM	Seres Therapeutics to Host Second Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on August 8, 2023 (Business Wire)
Jul-14-23 04:01PM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.09%
Jul-07-23 10:17AM	Seres Therapeutics (NASDAQ:MCRB) shareholders have endured a 47% loss from investing in the stock five years ago (Simply Wall St.)
Jun-21-23 09:00AM	Seres Therapeutics Named to TIME100 Most Influential Companies List (Business Wire) +6.52%
Jun-17-23 03:45PM	Seres Therapeutics and Nestlé Health Science Present Late-Breaking Data on VOWST, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023 (Business Wire)
Jun-09-23 07:00AM	Seres Therapeutics to Present at Goldman Sachs Global Healthcare Conference (Business Wire)
07:00AM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-05-23 07:00AM	Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection (Business Wire)

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Young Teresa L.	See Remarks	Feb 18 '25	Sale	0.81	3,338	2,704	97,536	Feb 19 08:11 PM
Henn Matthew R.	See Remarks	Feb 18 '25	Sale	0.81	3,953	3,204	84,443	Feb 19 08:10 PM
Shaff Eric D.	CEO and President	Feb 18 '25	Sale	0.81	12,726	10,314	192,039	Feb 19 08:08 PM
DesRosier Thomas	Chief Legal Officer and EVP	Feb 18 '25	Sale	0.81	4,300	3,485	142,456	Feb 19 08:07 PM
von Moltke Lisa	See Remarks	Feb 18 '25	Sale	0.81	4,416	3,579	39,875	Feb 19 08:05 PM
DesRosier Thomas	Chief Legal Officer and EVP	Nov 18 '24	Sale	0.54	878	475	135,192	Nov 19 04:21 PM
von Moltke Lisa	See Remarks	Nov 18 '24	Sale	0.54	977	528	32,415	Nov 19 04:20 PM
Shaff Eric D.	CEO and President	Nov 18 '24	Sale	0.54	2,505	1,355	170,389	Nov 19 04:15 PM
Young Teresa L.	See Remarks	Nov 18 '24	Sale	0.54	735	398	90,404	Nov 19 04:15 PM
Henn Matthew R.	See Remarks	Nov 18 '24	Sale	0.54	927	501	77,770	Nov 19 04:15 PM
von Moltke Lisa	See Remarks	Oct 27 '24	Option Exercise	0.00	13,744	0	34,757	Oct 29 06:33 PM
von Moltke Lisa	See Remarks	Oct 28 '24	Sale	0.69	4,334	2,991	30,423	Oct 29 06:33 PM
Henn Matthew R.	See Remarks	Oct 27 '24	Option Exercise	0.00	12,622	0	79,869	Oct 29 06:27 PM
Henn Matthew R.	See Remarks	Oct 28 '24	Sale	0.69	3,984	2,749	75,885	Oct 29 06:27 PM
DesRosier Thomas	Chief Legal Officer and EVP	Oct 27 '24	Option Exercise	0.00	13,500	0	137,673	Oct 29 06:26 PM
DesRosier Thomas	Chief Legal Officer and EVP	Oct 28 '24	Sale	0.69	4,259	2,939	133,414	Oct 29 06:26 PM
Shaff Eric D.	CEO and President	Oct 27 '24	Option Exercise	0.00	27,837	0	173,830	Oct 29 06:24 PM
Shaff Eric D.	CEO and President	Oct 28 '24	Sale	0.69	8,748	6,037	165,082	Oct 29 06:24 PM
Young Teresa L.	See Remarks	Oct 27 '24	Option Exercise	0.00	11,360	0	91,466	Oct 29 06:23 PM
Young Teresa L.	See Remarks	Oct 28 '24	Sale	0.69	2,983	2,059	88,483	Oct 29 06:23 PM
DesRosier Thomas	Chief Legal Officer and EVP	Aug 16 '24	Sale	0.84	873	733	124,173	Aug 19 05:48 PM
von Moltke Lisa	See Remarks	Aug 16 '24	Sale	0.84	973	817	21,013	Aug 19 05:45 PM
Henn Matthew R.	See Remarks	Aug 16 '24	Sale	0.84	923	775	67,247	Aug 19 05:42 PM
Shaff Eric D.	CEO and President	Aug 16 '24	Sale	0.84	2,518	2,115	145,993	Aug 19 05:38 PM
Young Teresa L.	See Remarks	Aug 16 '24	Sale	0.84	728	612	80,106	Aug 19 05:36 PM
Ege David S.	See Remarks	Aug 16 '24	Sale	0.84	1,128	948	77,575	Aug 19 05:29 PM
Young Teresa L.	See Remarks	Aug 05 '24	Sale	1.08	24,480	26,534	78,178	Aug 06 04:15 PM
von Moltke Lisa	See Remarks	May 15 '24	Sale	0.94	939	883	19,017	May 17 08:23 PM
Shaff Eric D.	CEO and President	May 15 '24	Sale	0.94	2,435	2,289	140,698	May 17 08:18 PM
Young Teresa L.	See Remarks	May 15 '24	Sale	0.94	703	661	17,658	May 17 08:18 PM
Henn Matthew R.	See Remarks	May 15 '24	Sale	0.94	891	838	65,357	May 17 08:17 PM
Ege David S.	See Remarks	May 15 '24	Sale	0.94	1,090	1,025	75,734	May 17 08:16 PM
DesRosier Thomas	Chief Legal Officer and EVP	May 15 '24	Sale	0.94	843	792	122,390	May 17 08:14 PM

IBIO

iBio Inc

MCRB

Seres Therapeutics Inc

Upgrade your FINVIZ experience